Illumina specializes in sequencing and array-based solutions tailored for genetic and genomic analysis. The company's primary products include advanced sequencing platforms, library preparation kits, and array technologies. These products support a range of applications such as whole-genome sequencing, gene expression analysis, and genetic variation studies. Illumina's offerings are widely used in life sciences research and clinical markets, particularly in areas like noninvasive prenatal testing (NIPT) and cancer genomics, where they play a crucial role in diagnostics and personalized treatment planning.
Illumina operates within the life sciences, clinical, and applied markets, including consumer genomics and agrigenomics. The company's revenue is predominantly generated through the sale of sequencing and array-based instruments and consumables, with consumables accounting for the largest share of its total revenue. Illumina also provides services like whole-genome sequencing and NIPT through its CLIA-certified laboratory. The primary client base consists of genomic research centers, academic institutions, government laboratories, hospitals, and companies in the pharmaceuticals, biotechnology, and consumer genomics sectors.
Operationally, Illumina maintains a global market presence, with nearly half of its revenue in 2024 coming from international sales. The company supports its operations through manufacturing facilities that comply with ISO 13485 quality management standards. Key factors impacting Illumina's business performance include its ability to innovate and maintain its intellectual property portfolio, which consists of over 1,300 issued U.S. patents. The company also faces significant competition within the genomics industry from other well-resourced entities.